


# 21<sup>st</sup> Annual Meeting



Innsbruck, Austria


September 13 - 15, 2007



in cooperation with the



**"DC-THERA European Network"**





Dear Colleagues!

On behalf of the local organizing committee I cordially welcome you in Innsbruck at the 21st Annual Meeting of the European Macrophage and Dendritic Cells Society (EMDS). As a premiere this meeting is organized together with the European DC—THERA network which set up a very interesting imaging workshop being open to all EMDS participants on Saturday, Sept 15<sup>th</sup>, afternoon.



Research on macrophages/ DCs and infectious diseases has been a central research focus of several groups here in Innsbruck. Major emphasis has been put on studying host- pathogen interaction, the regulatory networks between iron homeostasis and immunity, macrophage effector pathways including nitric oxide production, neopterin formation and indoleamine dioxygenase activation, antigen recognition, containment and processing by macrophages/DCs, immune cell/DC migration, intestinal immunity et cetera. DCs were first brought to Austria from their place of discovery, the Rockefeller University (RM Steinman & Z. Cohn), by researchers from this university (N Romani) some 20 years ago. Innsbruck was the initial center for dissemination of DC knowledge across many European countries. Innsbruck was also the place where one of the first clinical trials, using DC for tumor therapy, was initiated in 1997.

This existing focus on macrophages and DCs was a main reason why in 2004 Innsbruck Medical University (MUI) chose “Infection and Immunity” as a main strategic research area. In addition, a postgraduate doctoral study programme (MD/PhD-programme) with the topic “Infectious diseases: molecular mechanisms” has already been established at the MUI in 2000 which perfectly complements this research focus.

This year’s EMDS meeting addresses several interesting aspects of macrophage and DC biology which have not been part of recent EMDS meeting. We are grateful to the exceptional scientists who were willing to accept our invitation as speakers and to present state of the art lectures at this meeting. In addition, almost 100 high quality abstracts were submitted, from which 30 were selected for oral presentation. In accordance with the traditional format of the EMDS meetings, there is only one lecture room and the poster presentations, coffee breaks and the industrial exhibition are in one and the same area a scenario which promotes the scientific exchange and puts the poster discussions into the center of the meeting.

The conference venue was a former catholic church, monastery and school until the 1980s when the order moved to a new building at the outskirts of Innsbruck.

The conference dinner will be held at the Urich-House at the Bergisel in the South of Innsbruck. The Bergisel is a traditional place, not only because of the close-by ski-jumping stadium but more importantly for historical reasons since there were the major fightings during the liberation war of 1809 when French and Bavarian troops moved in to Tyrol and were opposed by a Tyrolean army of farmers. In addition, from the balcony of the Urich-House you can anticipate a beautiful view on Innsbruck and the surrounding mountains.

I wish you all an enjoyable, scientifically rewarding and stimulating meeting here in Innsbruck.

Günther Weiss

On the behalf of the local organizing committee and all helper, supporters and assistants.

## <Organising Committee>

Günter Weiss, MD - Head      email: guenter.weiss@i-med.ac.at  
Gernot Fritsche  
Dietmar Fuchs  
Christine Heufler-Tiefenthaler  
Arthur Kaser  
Nikolaus Romani  
Heribert Stoiber  
Martin Thurnher  
Herbert Tilg

## <EMDS Council>

Regine Landmann (Basel) - President  
Robert H.J. Beelen (Amsterdam)  
Christian Bogdan (Erlangen)  
Manfred Lutz (Würzburg)  
Caetano Reis e Sousa (London)  
Alexander Steinkasserer (Erlangen)  
Loems Ziegler-Heitbrock (Leicester)

## <DC-THERA European Network>

Carl Figdor, Imaging Platform Leader (Nijmegen)  
Jon Austyn, Coordinator (Oxford)

## <Congress organisation>

pdl congress management  
Andreas-Hofer-Str. 6, A-6020 Innsbruck  
phone    +43(0)512 - 579497  
fax       +43(0)512 - 579497 - 55  
info@congressinfo.net  
www.congressinfo.net

## <Registration Fee>

	paid before June 3rd	paid after June 3rd
Non-Member	Eur 260	Eur 310
Member of the EMDS	Eur 210	Eur 260
Student	Eur 160	Eur 210
Per day registration at the venue		Eur 120

## <Awards, Poster price>

Members of the EMDS (below the age of 35) joining the Annual EMDS Meeting are welcome to apply for a **Young Investigator Travel Award** (information: [www.macrophage.de/yita.htm](http://www.macrophage.de/yita.htm)).

Additionally up to five posters will be honoured with a **Poster Price** (information: [www.macrophage.de/pp.htm](http://www.macrophage.de/pp.htm)).



**PEPROTECH**  
CYTOKINES ARE OUR BUSINESS

***a fresh approach  
to cytokines***

***next day delivery  
custom vial sizes  
manufacturer of our full product range***


**PeproTech France**  
tel +33 (0)1 46 24 58 20  
[info@peprotechfr.com](mailto:info@peprotechfr.com)  
[www.peprotechfr.com](http://www.peprotechfr.com)

**PeproTech EC Ltd**  
tel +44 (0)20 7610 3062  
[info@peprotech.co.uk](mailto:info@peprotech.co.uk)  
[www.peprotechec.com](http://www.peprotechec.com)

**PeproTech GmbH**  
tel +49 (0)40 734 35 77 70  
[info@peprotech.de](mailto:info@peprotech.de)  
[www.peprotech.de](http://www.peprotech.de)

## <Conference Venue>

Raiffeisensäule am Marktplatz  
Innrain 7, 6020 Innsbruck, Austria





## &lt;PROGRAM&gt;

## Program Overview

09:00		Symposium III: Intestinal macrophages and dendritic cells – From host pathogen inter- action to immune tolerance	Symposium VI: Inherited and acquired defects of phagocyte function
09:30			
10:00			
10:30			
11:00		COFFEE BREAK	COFFEE BREAK
11:30		Symposium IV: Antigen presentation by macrophages and DCs	Symposium VI: continued
12:00	Registration		
12:30			
13:00		LUNCH	LUNCH
13:30	OPENING	LUNCH	
14:00	Symposium I: Phagocyte innate resistance mechanisms	Symposium V: Iron metabolism and macrophage effector function	DC-THERA European Network – IMAGING Workshop
14:30			
15:00			
15:30			
16:00	Poster Session I with coffee and bisquits	Poster Session II with beer and prezel	
16:30			
17:00			
17:30	Symposium II: Macrophages/DC as therapeutic targets	EMDS Business Meeting	CLOSING REMARKS
18:00			
18:30			
19:00			
19:30	Welcome Reception	CONFERENCE DINNER	
	open end	open end	

## Thursday, September 13

### 13:30 **Opening**

*G. Weiss, Head of the Local Organising Committee*

*R. Landmann, President of the EMDS*

*C. Sorg, Rector of the Medical University Innsbruck, Austria*

### **Symposium I: Phagocyte innate resistance mechanisms**

**Chair:** *R. Landmann, Basel, Switzerland*

*C. Sorg, Innsbruck, Austria*

14:00 O\_1 **Neutrophil extracellular traps and metalloproteinases**  
*(C. Urban, Berlin, Germany)*

14:30 O\_2 **Pentraxins and beyond**  
*(A. Mantovani, Milan, Italy)*

15:00 O\_3 **The Macrophage Adhesion Molecule Sialoadhesin Modulates B cell Responses**  
*(Oetke C. et al., University of Dundee, Scotland)*

15:15 O\_4 **PTEN importantly contributes to PMN influx during pneumococcal pneumonia in vivo**  
*(Matt U. et al., CeMM - Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria)*

15:30 O\_5 **Senescence regulates macrophage polarization and angiogenesis at sites of tissue injury**  
*(Kelly J. et al., Washington University School of Medicine, US)*

15:45 O\_6 **LPS and interferons induce surface expression and activity of ADP-ribosyl-transferase ART2.1 on murine bone marrow-derived macrophages**  
*(Brass A. et al., University Medical Center Hamburg-Eppendorf, Germany)*

### 16:00 **Poster Session I**

Presentation of posters 1 – 32 (P\_1 – P\_32)



## Thursday, September 13

### **Symposium II: Macrophages/DC as therapeutic targets**

**Chair:** D. Fuchs, Innsbruck, Austria  
A. Steinkasserer, Erlangen, Germany

- 17:30** O\_7 Cytokine resistance pathways in macrophages and DCs  
(T. Decker, Vienna, Austria)
- 18:00** O\_8 New approaches in anticytokine therapies for inflammatory diseases  
(H. Tilg, Hall, Austria)
- 18:30** O\_9 IgG opsonization of HIV impedes provirus formation in and infection of dendritic cells and subsequent long-term transfer to T cells  
(Wilflingseder D. et al., Innsbruck Medical University, Austria)
- 18:45** O\_10 The adjuvant activity of Trehalose-6,6-dibehenate: activation of .....  
(Werninghaus K. et al., Technical University Munich, Germany)
- 19:00** O\_11 Macrophage responses to hypoxia and Angiopoietin-2  
(Lewis C.E. et al., University of Sheffield Medical School, UK)
- 19:15** O\_12 Role of PPAR-gamma in macrophages: involvement in Listeria infection-induced responses  
(Szanto A. et al., University of Debrecen, Hungary)
- 19:30** **Welcome Reception**



## Friday, September 14

### **Symposium III: Intestinal macrophages and dendritic cells – From host pathogen interaction to immune tolerance**

**Chair:** C. Bogdan, Erlangen, Germany  
H. Tilg, Hall, Austria

- 09:00** O\_13 Immunotolerance to bacterial colonisation in the gut  
(M. Hornef, Freiburg, Germany)
- 09:30** O\_14 Differential expression of TREM-1 in intestinal macrophages in IBD and normal control  
(C. Mueller, Bern, Switzerland)
- 10:00** O\_15 Capnocytophaga canimorsus prevents phagocytosis & killing by macrophages  
(Meyer S. et al., University of Basel, Switzerland)
- 10:15** O\_16 Hypoxia reprograms the transcriptome of iDC: modulation of the chemokine/receptor pathway  
(Ricciardi A. et al., Gaslini Institute, Genoa, Italy)
- 10:30** O\_17 Alternative macrophage activation correlates with reactivation and pathology in murine tuberculosis  
(Schreiber T. et al., Research Center Borstel, Germany)
- 10:45** O\_18 Th1/Th2 differentiation in the murine model of Leishmania major infection is controlled by dendritic cell differentiation state and their interaction with NKT cells  
(Wiethe C. et al., University Hospital Erlangen, Germany)
- 11:00** **COFFEE BREAK**

## Friday, September 14

### **Symposium IV: Antigen presentation by macrophages and DCs**

**Chair:** M. Lutz, Würzburg, Germany  
M. Thurnher, Innsbruck, Austria

- 11:30** O\_19 CD1 mediated Ag-presentation pathways linking immunity to lipid metabolism  
(G. de Libero, Basel, Switzerland)
- 12:00** O\_20 Differential intracellular localisation of novel stabilin-1 interacting synaptotagmin SI-Syt in human macrophages  
(Krusell L. et al., University of Heidelberg, Germany)
- 12:15** O\_21 Differentially expressed molecules during the maturation of dendritic cells  
(Ortner D. et al., Innsbruck Medical University, Austria)
- 12:30** O\_22 Abnormal Activation of RhoA and RhoB in SWAP-70-/- DCs Leads to Deficient Expression of Surface MHCII  
(Ocaña-Morgner C. et al., University of Technology, Dresden, Germany)
- 12:45** O\_23 Myeloid DC and not plasmacytoid DC or macrophages are essential for the activation of natural killer cells in visceral leishmaniasis  
(Schleicher U. et al., University Clinic of Freiburg, Germany)
- 13:00** O\_24 Absence of bystander tolerance to fetal calf serum in a peptide-specific dendritic cell vaccine model of autoimmunity  
(Röbner S. et al., University Hospital Erlangen, Germany)
- 13:15** O\_25 Expression of CD25 on myeloid dendritic cells as an accessory regulatory molecule  
(Driesen J. et al., University of Cologne, Germany)
- 13:30** LUNCH

## Friday, September 14

### **Symposium V: Iron metabolism and macrophage effector function**

**Chair:** M. Rehli, Regensburg, Germany  
G. Weiss, Innsbruck, Austria

- 14:30** O\_26 Iron homeostasis and macrophage infection  
(U.E. Schaible, London, UK)
- 15:00** O\_27 Hcpidin and antimicrobial peptides  
(T. Ganz, Los Angeles, US)
- 15:30** O\_28 Analysis of the mechanisms underlying trypanosomiasis-associated anemia with focus on erythrophagocytosis and iron-homeostasis  
(Stijlemans B. et al., Vrije Universiteit Brussel, Belgium)
- 15:45** O\_29 Salmonella typhimurium infection and iron metabolism in mice presenting constitutive hemolytic anemia  
(Canonne-Hergaux F. et al., Institut de Chimie des Substances Naturelles, Gif-sur-Yvette, France)
- 16:00** O\_30 Interferon- $\gamma$  limits the availability of iron for intramacrophage Salmonella typhimurium  
(Nairz M. et al., Innsbruck Medical University, Austria)
- 16:15** O\_31 Regulation of macrophage peroxiredoxins by nitric oxide  
(Abbas et al., Institut de Chimie des Substances Naturelles, Gif-sur-Yvette, France)
- 16:30** **Poster Session II**  
Presentation of posters 33 – 64 (P\_33 – P\_64)
- 18:00** **EMDS Business Meeting**
- 19:30** **CONFERENCE DINNER - Urichhaus**

The logo for Wyeth, featuring the word "Wyeth" in a large, bold, red serif font.

# BD Biosciences

The Brands You Trust  
The Support You Expect



**BD FACS™**



**BD Falcon™**



**BD Pharmingen™**



**BD BioCoat™**



**BD Gentest™**



Helping all people  
live healthy lives

**BD Biosciences**

POB 13, Erembodegem-Dorp 86  
B-9320 Erembodegem  
Belgium  
Tel.: (32) 2 400 98 95  
Fax: (32) 2 401 70 94  
help.biosciences@europe.bd.com  
bdbiosciences.com

## Saturday, September 15

### Symposium VI: Inherited and acquired defects of phagocyte function (1)

**Chair:** C. Heufler-Tiefenthaler, Innsbruck, Austria  
L. Ziegler-Heitbrock, Gautong, Germany

- 09:00** O\_32 TLR pathway defects  
(J.C. Bustamante, Paris, France)
- 09:30** O\_33 Perforins and hemophagocytosis  
(U. zur Stadt, Hamburg, Germany)
- 10:00** O\_34 Transcription factor pu.1 Controls transcription start site positioning and alternative TLR4 promoter usage  
(Lichtinger M. et al., University Regensburg, Germany)
- 10:15** O\_35 Deficiency of the PI3K regulatory subunit p85alpha upregulates TLR4 signaling in vitro and in vivo  
(Schabbauer G. et al., Medical University, Vienna, Austria)
- 10:30** O\_36 SOCS-3 in macrophages/neutrophils regulates susceptibility to Mycobacterium tuberculosis infection  
(Rückerl D. et al., Research Center Borstel, Germany)
- 10:45** O\_37 Underlying mechanisms by which IL-10 dependent alternatively activated macrophages limit inflammation-induced tissue damage: parasite infection as a model  
(Bosschaerts T. et al., Vrije Universiteit Brussel, Belgium)
- 11:00** COFFEE BREAK



## Saturday, September 15

### **Symposium VI: Inherited and acquired defects of phagocyte function (2)**

**Chair:** R. Beelen, Amsterdam, Holland  
N. Romani, Innsbruck, Austria

- 11:30** O\_38 Defects of DC migration and function  
(P.-A. Oldenborg, Umeå, Sweden)
- 12:00** O\_39 Identification and characterization of novel scavenger macrophages of apoptotic thymocytes in the human thymus  
(Takahashi K. et al., Okayama University Medical School, Japan)
- 12:15** O\_40 Effects of Mycobacterium tuberculosis on DC apoptosis, maturation and oxygen free radicals production  
(Zenaro E. et al., University of Verona, Verona, Italy)
- 12:30** O\_41 Herpes Simplex Virus Type 1 (HSV-1) Induces CD83 Degradation in Mature Dendritic Cells with Immediate Early Kinetics via the Cellular Proteasome  
(Kummer M. et al., University Hospital Erlangen, Erlangen, Germany)
- 12:45** O\_42 Activin A induces dendritic cell migration through the secondary production of CXCL12 and CXCL14  
(Salogni L. et al., University of Brescia, Italy)
- 13:00** LUNCH

## Saturday, September 15

### DC-THERA European Network – IMAGING Workshop

**Chair:** C. Figdor, *Imaging Platform Leader (Nijmegen)*

**14:00** O\_43 High definition flow cytometry: unravelling the immune response  
*(P.K. Chattopadhyay, Vaccine Research Center, NIAID, NIH, US)*

**14:35** O\_44 Migration of T cell within lymphoid organs  
*(R. Forster, Hannover Medical School, Germany)*

**15:10** O\_45 Amoeboid T cell migration and interaction with DC  
*(P. Friedl, University of Wurzburg, Germany)*

**15:45** **COFFEE BREAK**

**16:15** O\_46 Imaging immune responses in vivo  
*(L. Fetler, Institute Curie, France)*

**16:50** O\_47 MRI cell tracking using magnetic nanoparticles for non invasive monitoring of cell therapy  
*(J. Bulte, The Johns Hopkins University School of Medicine, US)*

**17:25** O\_48 Tracking and monitoring DC based vaccines in melanoma patients  
*(J. de Vries, University of Nijmegen, The Netherlands)*

**18:00** **CLOSING REMARKS**

## Sicherheit durch gezielte Ersttherapie\*



Bei schweren Haut- und Weichgewebsinfektionen verursacht durch  
g+ Erreger einschließlich MRSA, MRSE, MSSA, KoNS, VRSA, VRE, GISA  
\*Arbeit RD et al.Clin.Infect.Dis 2004;44:1062-66



Once-A-Day  
**CUBICIN**<sup>®</sup>  
(daptomycin for injection)

### FACHKURZINFORMATION

#### **BEZEICHNUNG DES ARZNEIMITTELS:**

CUBICIN 350 mg - Pulver für ein Konzentrat zur Herstellung einer Infusionslösung  
CUBICIN 500 mg - Pulver für ein Konzentrat zur Herstellung einer Infusionslösung

#### **QUALITATIVE UND QUANTITATIVE ZUSAMMENSETZUNG**

**CUBICIN 350 mg:**  
Eine Durchstechflasche enthält 350 mg Daptomycin.  
Ein ml enthält 50 mg Daptomycin nach Rekonstitution mit 7 ml Natriumchloridlösung 9 mg/ml ( 0,9%) oder Wasser für Injektionszwecke.

#### **CUBICIN 500 mg**

Eine Durchstechflasche enthält 500 mg Daptomycin.  
Ein ml enthält 50 mg Daptomycin nach Rekonstitution mit 10 ml Natriumchloridlösung 9 mg/ml ( 0,9%) oder Wasser für Injektionszwecke.

#### **ANWENDUNGSGEBIETE**

CUBICIN ist für die Behandlung komplizierter Haut- und Weichteilinfektionen bei Erwachsenen angezeigt. Daptomycin ist ausschließlich gegen Gram-positive Bakterien aktiv. Im Fall von Mischinfektionen, bei denen der Verdacht auf Gram-negative und/oder bestimmte Arten anaerober Bakterien besteht, sollte CUBICIN gemeinsam mit (einem) geeigneten antibakteriellen Wirkstoff(en) angewendet werden.  
Die allgemein anerkannten Richtlinien für den angemessenen

Gebrauch von antimikrobiellen Wirkstoffen sind zu berücksichtigen.

#### **GEGENANZEIGEN**

Überempfindlichkeit gegen den Wirkstoff oder einen der sonstigen Bestandteile.

#### **SONSTIGE BESTANDTEILE**

Natriumhydroxid

#### **PHARMAZEUTISCHER UNTERNEHMER**

Novartis Europharm Limited  
Wimblehurst Road  
Horsham  
West Sussex, RH12 5AB, Vereinigtes Königreich

**ABGABE:** Rezept- und apothekenpflichtig

#### **PHARMAKOTHERAPEUTISCHE GRUPPE:**

Antibakterielle Substanzen zur systemischen Anwendung,  
Sonstige antibakterielle Substanzen, ATC-Code: J01XX09

Informationen betreffend Warnhinweise und Vorsichtsmaßnahmen für die Anwendung, Wechselwirkung mit anderen Mitteln, Nebenwirkungen und Gewöhnungseffekte sind den veröffentlichten Fachinformationen zu entnehmen. Novartis Pharma GmbH, Brunner Str. 59, 1235 Wien, Tel. 0043 1 86657 - 0, Fax 0043 1 86657 - 739.

## **We like to thank all our sponsors for their support**

(alphabetical list at time of printing)

AbD Serotec

Amt der Tiroler Landesregierung

BD Biosciences

Becton Dickinson Austria GmbH

Eubio

Milteny Biotec

Novartis Pharma GmbH

Peptotech Ec

Pfizer Austria

Profos AG

R + D Systeme GmbH

Stadt Innsbruck

THP Medical Products GmbH

Wyeth Lederle Pharma GmbH